144 related articles for article (PubMed ID: 16178722)
1. BX471: a CCR1 antagonist with anti-inflammatory activity in man.
Horuk R
Mini Rev Med Chem; 2005 Sep; 5(9):791-804. PubMed ID: 16178722
[TBL] [Abstract][Full Text] [Related]
2. Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis.
He M; Horuk R; Moochhala SM; Bhatia M
Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1173-80. PubMed ID: 17234893
[TBL] [Abstract][Full Text] [Related]
3. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis.
Lebre MC; Vergunst CE; Choi IY; Aarrass S; Oliveira AS; Wyant T; Horuk R; Reedquist KA; Tak PP
PLoS One; 2011; 6(7):e21772. PubMed ID: 21747955
[TBL] [Abstract][Full Text] [Related]
4. BX-471 Berlex.
Elices MJ
Curr Opin Investig Drugs; 2002 Jun; 3(6):865-9. PubMed ID: 12137405
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1.
Liang M; Mallari C; Rosser M; Ng HP; May K; Monahan S; Bauman JG; Islam I; Ghannam A; Buckman B; Shaw K; Wei GP; Xu W; Zhao Z; Ho E; Shen J; Oanh H; Subramanyam B; Vergona R; Taub D; Dunning L; Harvey S; Snider RM; Hesselgesser J; Morrissey MM; Perez HD
J Biol Chem; 2000 Jun; 275(25):19000-8. PubMed ID: 10748002
[TBL] [Abstract][Full Text] [Related]
6. Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modulating neutrophil recruitment.
He M; Horuk R; Bhatia M
Pancreas; 2007 Mar; 34(2):233-41. PubMed ID: 17312463
[TBL] [Abstract][Full Text] [Related]
7. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection.
Horuk R; Clayberger C; Krensky AM; Wang Z; Grone HJ; Weber C; Weber KS; Nelson PJ; May K; Rosser M; Dunning L; Liang M; Buckman B; Ghannam A; Ng HP; Islam I; Bauman JG; Wei GP; Monahan S; Xu W; Snider RM; Morrissey MM; Hesselgesser J; Perez HD
J Biol Chem; 2001 Feb; 276(6):4199-204. PubMed ID: 11054419
[TBL] [Abstract][Full Text] [Related]
8. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice.
Anders HJ; Belemezova E; Eis V; Segerer S; Vielhauer V; Perez de Lema G; Kretzler M; Cohen CD; Frink M; Horuk R; Hudkins KL; Alpers CE; Mampaso F; Schlöndorff D
J Am Soc Nephrol; 2004 Jun; 15(6):1504-13. PubMed ID: 15153561
[TBL] [Abstract][Full Text] [Related]
9. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome.
Vielhauer V; Berning E; Eis V; Kretzler M; Segerer S; Strutz F; Horuk R; Gröne HJ; Schlöndorff D; Anders HJ
Kidney Int; 2004 Dec; 66(6):2264-78. PubMed ID: 15569315
[TBL] [Abstract][Full Text] [Related]
10. Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.
Ninichuk V; Gross O; Reichel C; Khandoga A; Pawar RD; Ciubar R; Segerer S; Belemezova E; Radomska E; Luckow B; Perez de Lema G; Murphy PM; Gao JL; Henger A; Kretzler M; Horuk R; Weber M; Krombach F; Schlöndorff D; Anders HJ
J Am Soc Nephrol; 2005 Apr; 16(4):977-85. PubMed ID: 15716328
[TBL] [Abstract][Full Text] [Related]
11. CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.
Horuk R; Shurey S; Ng HP; May K; Bauman JG; Islam I; Ghannam A; Buckman B; Wei GP; Xu W; Liang M; Rosser M; Dunning L; Hesselgesser J; Snider RM; Morrissey MM; Perez HD; Green C
Immunol Lett; 2001 Apr; 76(3):193-201. PubMed ID: 11306147
[TBL] [Abstract][Full Text] [Related]
12. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation.
Vaidehi N; Schlyer S; Trabanino RJ; Floriano WB; Abrol R; Sharma S; Kochanny M; Koovakat S; Dunning L; Liang M; Fox JM; de Mendonça FL; Pease JE; Goddard WA; Horuk R
J Biol Chem; 2006 Sep; 281(37):27613-20. PubMed ID: 16837468
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage.
Bedke J; Kiss E; Schaefer L; Behnes CL; Bonrouhi M; Gretz N; Horuk R; Diedrichs-Moehring M; Wildner G; Nelson PJ; Gröne HJ
Am J Transplant; 2007 Mar; 7(3):527-37. PubMed ID: 17229070
[TBL] [Abstract][Full Text] [Related]
14. CCR1 antagonists in clinical development.
Pease JE; Horuk R
Expert Opin Investig Drugs; 2005 Jul; 14(7):785-96. PubMed ID: 16022568
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic strategies for chronic inflammatory diseases.
Ferrer E
Drug News Perspect; 2006; 19(6):353-8. PubMed ID: 16971972
[TBL] [Abstract][Full Text] [Related]
16. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.
Anders HJ; Vielhauer V; Frink M; Linde Y; Cohen CD; Blattner SM; Kretzler M; Strutz F; Mack M; Gröne HJ; Onuffer J; Horuk R; Nelson PJ; Schlöndorff D
J Clin Invest; 2002 Jan; 109(2):251-9. PubMed ID: 11805137
[TBL] [Abstract][Full Text] [Related]
17. CCR1 antagonists for the treatment of autoimmune diseases.
Gladue RP; Zwillich SH; Clucas AT; Brown MF
Curr Opin Investig Drugs; 2004 May; 5(5):499-504. PubMed ID: 15202722
[TBL] [Abstract][Full Text] [Related]
18. The use of salt-inducible kinase inhibitors to treat autoimmune and inflammatory diseases: evaluation of WO2013136070.
Norman P
Expert Opin Ther Pat; 2014 Aug; 24(8):943-6. PubMed ID: 24745372
[TBL] [Abstract][Full Text] [Related]
19. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
20. CCR1 chemokine receptor antagonist.
Saeki T; Naya A
Curr Pharm Des; 2003; 9(15):1201-8. PubMed ID: 12769747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
